Allergan PLC. (AGN) Stake Lessened by Wayne Hummer Investments L.L.C.
Wayne Hummer Investments L.L.C. decreased its position in Allergan PLC. (NYSE:AGN) by 21.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,348 shares of the company’s stock after selling 378 shares during the quarter. Wayne Hummer Investments L.L.C.’s holdings in Allergan PLC. were worth $328,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GWM Advisors LLC grew its stake in shares of Allergan PLC. by 0.4% in the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after acquiring an additional 5 shares in the last quarter. Burns J W & Co. Inc. NY grew its stake in shares of Allergan PLC. by 0.7% in the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after acquiring an additional 6 shares in the last quarter. Gilder Gagnon Howe & Co. LLC grew its stake in shares of Allergan PLC. by 0.5% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after acquiring an additional 9 shares in the last quarter. Trust Co grew its stake in shares of Allergan PLC. by 0.8% in the 1st quarter. Trust Co now owns 1,224 shares of the company’s stock worth $292,000 after acquiring an additional 10 shares in the last quarter. Finally, Berkeley Capital Partners LLC grew its stake in shares of Allergan PLC. by 0.3% in the 2nd quarter. Berkeley Capital Partners LLC now owns 3,721 shares of the company’s stock worth $905,000 after acquiring an additional 10 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/12/allergan-plc-agn-stake-lessened-by-wayne-hummer-investments-l-l-c.html.
AGN has been the subject of several recent analyst reports. UBS AG reiterated a “buy” rating and issued a $275.00 target price on shares of Allergan PLC. in a research note on Monday, May 15th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. ValuEngine lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, June 8th. Finally, Mizuho reduced their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research report on Friday, June 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $275.49.
Shares of Allergan PLC. (AGN) opened at 232.38 on Tuesday. The stock has a market capitalization of $77.69 billion, a P/E ratio of 7.08 and a beta of 1.18. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company has a 50-day moving average of $235.17 and a 200-day moving average of $237.15.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the previous year, the firm earned $3.35 EPS. The firm’s revenue was up 8.8% compared to the same quarter last year. On average, analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.20%. Allergan PLC.’s dividend payout ratio is presently 9.95%.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.